Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

Breast Neoplasm Female Clinical Trial

Official title:

Single Center, Placebo-Controlled Trial of Oral High-Molecular Weight Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03384095
• Other study ID #: IUSCC-0533
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 14, 2018
• Est. completion date: December 14, 2018

Study information

• Verified date: December 2018
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, double-blinded, placebo-controlled, randomized Phase II trial to determine whether oral hyaluronic acid will prevent aromatase inhibitor (AI)-associated arthralgias. Subjects must have ER/PR-positive breast cancer tumor with history of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) which resolved after cessation of their AI (anastrazole or letrozole) within 90 days of enrollment. Subjects will be stratified by initial AI, thus within each initial AI, subjects will be randomized to receive either the experimental treatment (hyaluronic acid) or placebo. Subjects will begin the assigned treatment for 2 weeks prior to transitioning to the second AI. Evaluations will be taken at baseline, 6 weeks (1 month on study drug and AI), 14 weeks (3 months on study drug and AI), and at 26 weeks (6 months on study drug and AI). Treatment with hyaluronic acid and placebo will last for 26 weeks total.

Description:

Primary Objective To determine whether oral HA will prevent AI-induced arthralgias and preserve physical function.

Secondary Objectives

1. To explore whether oral HA will have an acceptable safety and tolerability profile.

2. To determine whether oral HA will prevent other AI associated symptoms as assessed by patient reported outcomes (PRO's).

3. To assess how many of the subjects are 90% compliant with taking the HA as directed.

Exploratory Objective To determine if mi486, (a microRNA enriched in skeletal muscle) and other biomarkers associated with AIMSS (TNF, IL-6, IL-17) vary with the administration of HA.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 14, 2018
• Est. primary completion date: December 14, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Study Population ER/PR-Positive Breast Cancer Subjects whose AIMSS resolved with cessation of their AI and are candidates for switching to a different AI and who meet the inclusion and exclusion criteria will be eligible for participation in this study.

Inclusion Criteria

1. Age = 18 years old.

2. Had been taking anastrazole or letrozole, and discontinued it within the past 90 days due to pain and/or stiffness. The AI-related pain/stiffness must have resolved.

3. Prior tamoxifen use is allowed.

4. A prior switch from exemestane is allowed.

5. Women who have undergone a total mastectomy or breast conserving surgery for Stage 0-3 breast cancer +/- chemotherapy, +/- antiHer2Neu therapy, +/- radiotherapy.

6. Must have ER and/or PR positive tumors.

7. Women who are postmenopausal by the presence of natural amenorrhea = 12 months or by ovarian ablation (bilateral oophorectomy, radiation, or administration of a gonadotropin-releasing hormone agonist).

8. Eastern Cooperative Oncology Group Performance Score (ECOG PS) 0-3 (Appendix II).

9. Patients may or may not be taking non-opioid analgesics.

10. Adequate renal and hepatic function:

i) Include only subjects with AST and ALT < 2.0 × ULN; AP < 1.5 × ULN; total bilirubin < 1.2 × ULN ii) Include only subjects with as calculated creatinine clearance (CrCl) > 60 mL/min determined by the central laboratory using the modified Cockcroft-Gault equation; blood urea nitrogen (BUN) < 1.5 × upper limit of normal (ULN)

11. Written informed consent from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria

1. Presence of residual or recurrent cancer.

2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

3. Consumption of HA-containing supplements in the four weeks prior to study.

4. Known allergy to microcrystalline cellulose or HA. Any questionable reaction to injected HA will be thoroughly investigated.

5. Prolonged systemic corticosteroid treatment, except for topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops or local insertion (i.e., intra-articular). A short duration of systemic corticosteroids is allowed but not within 30 days prior to registration.

6. Self-reported compliance issues and lack of regular prescription filling.

7. Previous diagnosis of fibromyalgia and/or rheumatoid arthritis.

Related Conditions & MeSH terms

• Arthralgia
• Breast Neoplasm Female
• Breast Neoplasms

Intervention

Drug:
• Hyaluronic Acid (HA)
Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks

Other:
• Placebo
Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks

Locations

Country	Name	City	State
United States	Indiana University Health North Hospital	Carmel	Indiana
United States	Indiana University Health Hospital	Indianapolis	Indiana
United States	Indiana University Health Melvin and Bren Simon Cancer Center	Indianapolis	Indiana
United States	Spring Mill Medical Center	Indianapolis	Indiana

Sponsors (3)

Lead Sponsor	Collaborator
Erin Newton	Indiana University, NOW Foods

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in mean change in joint pain between HA and placebo groups	As measured by the Brief Pain Inventory - Short Form (BPI-SF) questions #3-#6, #9A-G. This 14-item questionnaire was developed for use in patients with cancer that uses a scale from 0 to 10 to assess worst pain, pain severity, and pain interference over the past week. The first 8 items have to do with the severity of the pain, and the remaining 7 items ask about how the pain has affected function.	14 weeks
Secondary	Incidence of treatment-emergent adverse events (i.e. safety and tolerability of HA)	Summary of adverse events as measured by CTCAE v4.0	30 weeks
Secondary	Difference in mean joint symptoms between HA and placebo groups	As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) scores. This questionnaire assesses the three domains of pain, stiffness, and physical function in the lower extremities over the past 7 days. It is scored from 0 to 100, with higher scores indicating worse symptoms.	6, 14, and 26 weeks
Secondary	Difference in mean joint function between HA and placebo groups	As measured by Disabilities of the Arm, Shoulder, and Hand questionnaire (QuickDASH) scores. This 11-item instrument assesses physical function and symptoms in patients with musculoskeletal disorders of the upper limbs. It is a questionnaire scored from 1 to 5, with the higher score indicating worse symptoms, and there is a validated method to calculate a single Disability/Symptom Score.	6, 14, and 26 weeks
Secondary	Difference in mean quality of sleep between HA and placebo groups	As measured by Pittsburgh Sleep Quality Index (PSQI) scores. This an 18-item instrument produces a global sleep-quality score and the following component scores: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction.	6, 14, and 26 weeks
Secondary	Difference in global change between HA and placebo groups	As measured by Patient's Global Impression of Change scale (PGIC) scores	6, 14, and 26 weeks
Secondary	Difference in mean change in WOMAC subscale 1 scores between HA and placebo groups	As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) subscale 1 scores. As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) scores. This questionnaire assesses the three domains of pain, stiffness, and physical function in the lower extremities over the past 7 days. It is scored from 0 to 100, with higher scores indicating worse symptoms.	6, 14, and 26 weeks
Secondary	Difference in mean change in WOMAC subscale 2 scores between HA and placebo groups	As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) subscale 2 scores. As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) scores. This questionnaire assesses the three domains of pain, stiffness, and physical function in the lower extremities over the past 7 days. It is scored from 0 to 100, with higher scores indicating worse symptoms.	6, 14, and 26 weeks
Secondary	Difference in mean change in WOMAC subscale 3 scores between HA and placebo groups	As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) subscale 3 scores. As measured by Western Ontario and McMaster osteoarthritis index (WOMAC) scores. This questionnaire assesses the three domains of pain, stiffness, and physical function in the lower extremities over the past 7 days. It is scored from 0 to 100, with higher scores indicating worse symptoms.	6, 14, and 26 weeks
Secondary	Time to discontinuation of second aromatase inhibitor due to AIMSS between HA and placebo groups	As measured by patient self-report of mediation compliance (medication diary) and chart review	26 weeks
Secondary	Proportion of patients that remain on second aromatase inhibitor between HA and placebo groups	As measured by patient self-report of mediation compliance (medication diary) and chart review	26 weeks
Secondary	Rate of 90% compliance between HA and placebo groups	As measured by patient self-report of mediation compliance (medication diary)	26 weeks
Secondary	Mean frequency of as needed analgesia between HA and placebo groups	As measured by patient self-report of mediation compliance (medication diary)	6, 14, and 26 weeks